Kazuhiro Shimada1,2, Takashi Ishikawa3, Akimitsu Yamada4, Sadatoshi Sugae4, Kazutaka Narui5, Daisuke Shimizu6, Takashi Chishima7, Itaru Endo4. 1. Department of Breast and Thyroid Surgery, Yokohama City University Medical Centre, Yokohama, Japan kazu90052003@yahoo.co.jp. 2. Department of Breast Surgery, Chigasaki Municipal Hospital, Chigasaki, Japan. 3. Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan. 4. Department of Gastrointestinal Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 5. Department of Breast and Thyroid Surgery, Yokohama City University Medical Centre, Yokohama, Japan. 6. Breast Centre, Yokohama City Minato Red Cross Hospital, Yokohama, Japan. 7. Department of Breast Surgery, Yokohama Rosai Hospital, Yokohama, Japan.
Abstract
BACKGROUND: Breast matrix-producing carcinomas (MPCs) are rare, and usually triple-negative (TNBC; i.e. oestrogen receptor-, progesterone receptor-, and human epidermal growth factor receptor 2-negative). This study evaluated the clinical features, immunohistochemical profiles, and pathological response to neoadjuvant chemotherapy (NAC) of patients with MPCs. PATIENTS AND METHODS: Five MPCs were identified among 247 patients with TNBC receiving anthracycline- and taxane-based NAC. Pathological response was assessed using surgical specimens. RESULTS: All tumours were histological grade 3 according to pre-treatment core biopsies. Mean Ki-67 and p53 positivity were 65% and 90%, respectively. All tumours were TNBC, and epidermal growth factor receptor-, cytokeratin 5/6-, and vimentin-positive. Grade 3 (pathological complete response) was achieved in 0% (0/5) and 32% (77/242) of those with MPCs and with TNBCs of no specific histological type, respectively, and grade 1a (poor response) in 80% (4/5) and 13% (31/242), respectively. CONCLUSION: MPCs are basal-type TNBCs expressing epithelial-mesenchymal transition markers, with a poor response to standard NAC. Further studies are needed to improve the treatment of this rare but aggressive tumour. Copyright
BACKGROUND: Breast matrix-producing carcinomas (MPCs) are rare, and usually triple-negative (TNBC; i.e. oestrogen receptor-, progesterone receptor-, and human epidermal growth factor receptor 2-negative). This study evaluated the clinical features, immunohistochemical profiles, and pathological response to neoadjuvant chemotherapy (NAC) of patients with MPCs. PATIENTS AND METHODS: Five MPCs were identified among 247 patients with TNBC receiving anthracycline- and taxane-based NAC. Pathological response was assessed using surgical specimens. RESULTS: All tumours were histological grade 3 according to pre-treatment core biopsies. Mean Ki-67 and p53 positivity were 65% and 90%, respectively. All tumours were TNBC, and epidermal growth factor receptor-, cytokeratin 5/6-, and vimentin-positive. Grade 3 (pathological complete response) was achieved in 0% (0/5) and 32% (77/242) of those with MPCs and with TNBCs of no specific histological type, respectively, and grade 1a (poor response) in 80% (4/5) and 13% (31/242), respectively. CONCLUSION: MPCs are basal-type TNBCs expressing epithelial-mesenchymal transition markers, with a poor response to standard NAC. Further studies are needed to improve the treatment of this rare but aggressive tumour. Copyright
Authors: Kazuyuki Hamada; Yusuke Aoki; Jun Yamamoto; Chihiro Hozumi; Ming Zhao; Takuya Murata; Norihiko Sugisawa; Michael Bouvet; Takuya Tsunoda; Robert M Hoffman Journal: In Vivo Date: 2021 Nov-Dec Impact factor: 2.155